| Catalog Number |
PR848259278 |
| CAS |
848259-27-8 |
| Description |
Pemafibrate is under investigation in clinical trial NCT03350165 (A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)). |
| Synonyms |
(R)-K-13675 |
| IUPAC Name |
(2R)-2-[3-[[1,3-benzoxazol-2-yl-[3-(4-methoxyphenoxy)propyl]amino]methyl]phenoxy]butanoic acid |
| Molecular Weight |
490.5 |
| Molecular Formula |
C28H30N2O6 |
| InChI |
ZHKNLJLMDFQVHJ-RUZDIDTESA-N |
| InChI Key |
InChI=1S/C28H30N2O6/c1-3-25(27(31)32)35-23-9-6-8-20(18-23)19-30(28-29-24-10-4-5-11-26(24)36-28)16-7-17-34-22-14-12-21(33-2)13-15-22/h4-6,8-15,18,25H,3,7,16-17,19H2,1-2H3,(H,31,32)/t25-/m1/s1 |
| Drug Categories |
Acids, Acyclic; Fatty Acids; Fatty Acids, Volatile; Fibric Acids; Heterocyclic Compounds, Fused-Ring; Lipid Modifying Agents; Lipid Modifying Agents, Plain; Lipid Regulating Agents; Lipids |
| Drug Interactions |
Acenocoumarol-The risk or severity of bleeding can be increased when Pemafibrate is combined with Acenocoumarol.
Acetohexamide-The risk or severity of hypoglycemia can be increased when Pemafibrate is combined with Acetohexamide.
Atorvastatin-The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Atorvastatin.
Bezafibrate-The risk or severity of adverse effects can be increased when Bezafibrate is combined with Pemafibrate.
Cerivastatin-The risk or severity of myopathy and rhabdomyolysis can be increased when Pemafibrate is combined with Cerivastatin. |
| Isomeric SMILES |
CC[C@H](C(=O)O)OC1=CC=CC(=C1)CN(CCCOC2=CC=C(C=C2)OC)C3=NC4=CC=CC=C4O3 |
| Standard |
In-house |
| Type |
Small Molecule |
| Therapeutic Category |
Hyperlipidaemia |
It should be noted that our service is only used for research, not for clinical use.
